Royalty Pharma plc (NASDAQ:RPRX) stock has gained around 53% year to date, as per data from Benzinga Pro.

On Monday, Royalty Pharma acquired the final portion of PTC Therapeutics Inc.’s (NASDAQ:PTCT) remaining royalty on Roche Holdings AG’s (OTC:RHHBY) Evrysdi for $240 million upfront and up to $60 million in sales-based milestones.

Evrysdi, marketed by Roche, is an orally administered survival motor neuron-2 (SMN2) splicing modifier for the treatment of spinal muscular atrophy (SMA).

Also Read: Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start

Evrysdi Regulatory Status And Sales

The FDA approved Evrysdi in 2020 and has treated over 21,000 patients worldwide.

In 2024, Evrysdi generated sales of approximately 1.6 billion Swiss francs ($1.9 billion), representing 18% year-over-year growth at constant exchange rates, and is projected to reach 2.3 billion Swiss francs ($2.9 ...